MATRIX METALLOPROTEINASES IN CHILDREN WITH CYSTIC FIBROSIS
The data of examination of 80 in-patients with the mixed form of cystic fibrosis (CF) are presented. All cases were divided into 3 groups according to the severity of the course of the disease. 16 conditionally healthy children made up a reference group. Determination of blood serum concentrations of interleukins (IL4, IL6), transforming growth factor-β1 (TGF-β1), matrix metalloproteinases MMP-2, MMP-8, MMP-9 and tissue inhibitor-TIMP-1 was performed by immunoassay ELISA method. The changes in the content of MMP and TIMP-1 in the blood serum of patients with various severity of the course of CF were found to be characterized by a significant decrease in MMP-8 and TIMP-1 concentrations, an increase in MMP-2 levels in children with moderate СF and a significant increase in MMP-9 concentrations, especially pronounced in patients with severe CF. At the same time, no definite dependence of the changes in MMP and TIMP-1 concentrations in the blood serum of patients on the frequency of exacerbations in the CF course and the dominant microbiota was found. Changes in the content of IL and TGF-β1 in the blood serum of children with the various severity of the course of CF were characterized by an increase in the concentrations of IL4 and TGFβ1 by more than 9.8 times, and IL6 - by 4.6 times if compared with the reference group. However, there no direct correlation was found between the changes in their production and the severity of the course of CF. The authors believe elevated levels of MMP, TIMP, and altered relationships between them can be used as biomarkers of the exacerbation of CF course in children.
About the authorsSmirnov I.E.
Yu E, Sharma S. Cystic Fibrosis. Treasure Island (FL): StatPearls Publishing; 2018.
The cystic fibrosis [Mukovistsidoz] / Eds. of N.I. Kapranov, N.Yu. Kashirskaya. Moscow; Medpractika. 2014.
Sanders DB, Fink AK. Background and Epidemiology. Pediatr Clin North Am. 2016; 63(4): 567-84.
Masekela R, Vosloo S, Venter SN, de Beer WZ, Green RJ. The lung microbiome in children with HIV-bronchiectasis: a cross-sectional pilot study. BMC Pulm Med. 2018; 18(1): 87. doi: 10.1186/s12890-018-0632-6.
Walicka-Serzysko K, Peckova M, Noordhoek JJ, Sands D, Drevinek P. Insights into the cystic fibrosis care in Eastern Europe: Results of survey. J Cyst Fibros. 2018. pii: S1569-1993(18)30088-2. doi: 10.1016/j.jcf.2018.04.003.
Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC et al. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest. 2016; 149(2): 390-400.
Schmidt M, Werbrouck A, Verhaeghe N, De Wachter E, Simoens S, Annemans L et al. Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations. J Cyst Fibros. 2018; 17(3): 306-15.
Hwang TC, Yeh JT, Zhang J, Yu YC, Yeh HI, Destefano S. Structural mechanisms of CFTR function and dysfunction. J Gen Physiol. 2018; 150(4): 539-70.
Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J et al. Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis. J Pediatr. 2017; 181(S): 45-51.
Bergougnoux A, Taulan-Cadars M, Claustres M, Raynal C. Current and future molecular approaches in the diagnosis of cystic fibrosis. Expert Rev Respir Med. 2018; 12(5): 415-26.
Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS. et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009; 154(2): 183-8.
Eickmeier O, Boom Lv, Schreiner F, Lentze MJ, NGampolo D, Schubert R. et al. Transforming growth factor β1 genotypes in relation to TGFβ1, interleukin-8, and tumor necrosis factor alpha in induced sputum and blood in cystic fibrosis. Mediators Inflamm. 2013; 913135. doi: 10.1155/2013/913135.
Nichols DP, Chmiel JF. Inflammation and its genesis in cystic fibrosis. Pediatr Pulmonol. 2015; 50 (Suppl 40): 39-56.
Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013; 68(12): 1157-62.
Breuer O, Caudri D, Akesson L, Ranganathan S, Stick SM, Schultz A. The clinical significance of oropharyngeal cultures in young children with cystic fibrosis. Eur Respir J. 2018; 51(5). pii: 1800238. doi: 10.1183/13993003.00238-2018.
Hurley MN. Staphylococcus aureus in cystic fibrosis: problem bug or an innocent bystander? Breathe (Sheff). 2018; 14(2): 87-90.
Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR, Liou TG. Microbial Interactions in the Cystic Fibrosis Airway. J Clin Microbiol. 2018. pii: JCM.00354-18. doi: 10.1128/JCM.00354-18.
Jaudszus A, Arnold C, Hentschel J, Hünniger K, Baier M, Mainz JG. Increased cytokines in cystic fibrosis patients’ upper airways during a new Ps. aeruginosa colonization. Pediatr Pulmonol. 2018. doi: 10.1002/ppul.24004.
Wojnarowski C, Frischer T, Hofbauer E, Grabner C, Mosgoeller W, Eichler I. et al. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. Eur Respir J. 1999; 14(5): 1136-44.
Smirnov I.E., Kucherenko A.G., Urtnasan Tsevegmid, Tylo O.V., Sorokina T.E., Volkov I.K. Interleukins and nitric oxide in developmental defects of the lungs and bronchi in children. Rossiyskiy pediatricheskiy zhurnal. 2010; 1: 12-17. (in Russian)
Smirnov I.E., Kustova O.V., Sorokina T.E., Kucherenko A.G. Markers of fibrosis in chronic bronchopulmonary pathology in children. Rossiyskiy pediatricheskiy zhurnal. 2015; 18(1): 14-20. (in Russian)
Cosgrove S, Chotirmall SH, Greene CM, McElvaney NG. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J Biol Chem. 2011; 286(9): 7692-704.
Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB et al. Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. J Cyst Fibros. 2017, 27(3): 309-19.
Smirnov I.E., Tarasova O.V., Lukina O.F., Kustova O.V., Sorokina T.E., Simonova O.I. Structural and functional state of the lungs in cystic fibrosis in children. Rossiyskiy pediatricheskiy zhurnal. 2015; 18 (1): 14-20. (in Russian)
De Boeck K, Vermeulen F, Dupont L. The diagnosis of cystic fibrosis. Presse Med. 2017; 46(6 Pt 2): 97-108.
Taylor SL , Rogers GB, Chen AC, Burr LD, McGuckin MA, Serisier DJ. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann Am Thorac Soc. 2015; 12(5): 701-7.
Esther CR Jr, Turkovic L, Rosenow T, Muhlebach MS, Boucher RC, Ranganathan S. et al. Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis. Eur Respir J. 2016;48(6): 1612-162.
Smirnov I.E., Sobolev S.S., Kucherenko A.G., Kustova O.V., Simonova O.I., Urtnasan Tsevegmid. Matrix metalloproteinases in children with chronic bronchopulmonary pathology. Rossiyskiy pediatricheskiy zhurnal. 2010; 6: 11-14. (in Russian)
Garratt LW, Sutanto EN, Ling KM, Looi K, Iosifidis T, Martinovich KM. et al. Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis. Eur Respir J. 2015; 46(2): 384-94.
Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J. 2011; 38(3): 721-7.
McMahan RS, Birkland TP, Smigiel KS, Vandivort TC, Rohani MG, Manicone AM et al. Stromelysin-2 (MMP10) Moderates Inflammation by Controlling Macrophage Activation. J Immunol. 2016; 197(3): 899-909.
Wight TN, Frevert CW, Debley JS, Reeves SR, Parks WC, Ziegler SF. Interplay of extracellular matrix and leukocytes in lung inflammation. Cell Immunol. 2017; 312(1): 1-14.
Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol. 2002; 18(1): 51-61.
Lagente V, Manoury B, Nénan S, Le Quément C, Martin-Chouly C, Boichot E. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz J Med Biol Res. 2005;38(10):1521-30.
Chakrabarti S, Patel KD. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res. 2005; 31(6): 599-621.
Roderfeld M, Rath T, Schulz R, Seeger W, Tschuschner A, Graf J. et al. Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation. J Cyst Fibros. 2009; 8(5): 338-47.
Devereux G, Steele S, Jagelman T, Fielding S, Muirhead R, Brady J et al. An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis. J Cystic Fibrosis. 2014; 13(5): 57-63.
Harris WT, Muhlebach MS, Oster RA, Knowles MR, Noah TL. Transforming growth factor-beta(1) in bronchoalveolar lavage fluid from children with cystic fibrosis. Pediatr Pulmonol. 2009; 44(11): 1057-64.
Maloney JP, Narasimhan J, Biller J. Decreased TGF-β1 and VEGF Release in Cystic Fibrosis Platelets: Further Evidence for Platelet Defects in Cystic Fibrosis. Lung. 2016; 194(5): 791-8.
Kramer EL, Clancy JP. TGFβ as a therapeutic target in cystic fibrosis. Expert Opin Ther Targets. 2018; 22(2): 177-89.
Gorinova Yu.V., Simonova O.I., Lazareva A.V., Chernevich V.P., Smirnov I.E. The experience of prolonged use of the inhalation solution of tobramycin in chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. Rossiyskiy pediatricheskiy zhurnal. 2015; 18(3): 50-3. (in Russian)
Blagovidov D.A., Simonova O.I., Kostinov M.P., Smirnov I.E. Pseudomonas aeruginosa infection in patients with chronic nonspecific lung diseases and its vaccination. Rossiyskiy pediatricheskiy zhurnal. 2015; 18(6): 54-60. (in Russian)
Ramsey KA, Schultz A, Stick SM. Biomarkers in Paediatric Cystic Fibrosis Lung Disease. Paediatr Respir Rev. 2015; 16(4): 213-8.
Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4): 360-7.
Sagel SD, Thompson V, Chmiel JF, Montgomery GS, Nasr SZ, Perkett E Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc. 2015; 12(5): 708-17.
Rogers GB Inflammation, age and changing microbiology: the search for causation in the cystic fibrosis airways. Eur. Resp. J. 2017 16(1); 50-5.
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.